{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:02:30Z","timestamp":1789527750916,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01523-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:06:02Z","timestamp":1789524362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score\u2013Matched Retrospective Cohort Study Using the TriNetX Network"],"prefix":"10.1007","volume":"57","author":[{"given":"Muhammad Ali Ibrahim","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Musa","family":"Mufarrih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa Ul Haque","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhameed","family":"Al-Sabban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihaal Prashant","family":"Karnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanmeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Canakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","first-page":"205031211668225","DOI":"10.1177\/2050312116682257","volume":"4","author":"I Makhoul","year":"2016","unstructured":"Makhoul I, Yacoub A, Siegel E. Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study. SAGE Open Med. 2016;4:2050312116682257.","journal-title":"SAGE Open Med"},{"issue":"4","key":"1523_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1053\/j.gastro.2008.01.039","volume":"134","author":"R Pannala","year":"2008","unstructured":"Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981\u20137. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.039.","journal-title":"Gastroenterology"},{"issue":"2","key":"1523_CR3","first-page":"135","volume":"1815","author":"B Bao","year":"2011","unstructured":"Bao B, Wang Z, Li Y, et al. The complexities of obesity, diabetes, and the development and progression of pancreatic cancer. Biochim Biophys Acta. 2011;1815(2):135\u201346.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1523_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.gastro.2007.10.040","volume":"134","author":"ST Chari","year":"2008","unstructured":"Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95\u2013101. https:\/\/doi.org\/10.1053\/j.gastro.2007.10.040.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1523_CR5","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.ijsu.2015.06.063","volume":"21","author":"T Salvatore","year":"2015","unstructured":"Salvatore T, Marfella R, Rizzo MR, Sasso FC. Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surg. 2015;21(Suppl 1):S72\u20137. https:\/\/doi.org\/10.1016\/j.ijsu.2015.06.063.","journal-title":"Int J Surg"},{"issue":"2","key":"1523_CR6","doi-asserted-by":"publisher","first-page":"e194742","DOI":"10.1172\/JCI194742","volume":"136","author":"P Cardoso","year":"2026","unstructured":"Cardoso P, Dennis JM, Pearson ER. GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. J Clin Invest. 2026;136(2):e194742.","journal-title":"J Clin Invest"},{"issue":"2","key":"1523_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","volume":"30","author":"HUH Ansari","year":"2024","unstructured":"Ansari HUH, Qazi SU, Sajid F, Altaf Z, Ghazanfar S, Naveed N, Ashfaq AS, Siddiqui AH, Iqbal H, Qazi S. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. 2024;30(2):160\u201371. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007.","journal-title":"Endocr Pract"},{"issue":"2","key":"1523_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight\/Obesity. JAMA Oncol. 2024;10(2):256\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1523_CR9","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(1):e2350408.","journal-title":"JAMA Netw Open"},{"key":"1523_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1472-6823-10-20","volume":"10","author":"DS Shyangdan","year":"2010","unstructured":"Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010;10:20. https:\/\/doi.org\/10.1186\/1472-6823-10-20.","journal-title":"BMC Endocr Disord"},{"issue":"8","key":"1523_CR11","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/dc17-1825","volume":"41","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018;41(8):1663\u201371. https:\/\/doi.org\/10.2337\/dc17-1825.","journal-title":"Diabetes Care"},{"issue":"2","key":"1523_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","volume":"98","author":"C Alves","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271\u201384. https:\/\/doi.org\/10.1016\/j.diabres.2012.09.008.","journal-title":"Diabetes Res Clin Pract"},{"key":"1523_CR13","doi-asserted-by":"publisher","unstructured":"Lauri G, Arcidiacono PG, Facciorusso A, Capurso G, Tacelli M. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Pancreatology. 2026;6:S1424-3903(26)00147-X. https:\/\/doi.org\/10.1016\/j.pan.2026.04.005","DOI":"10.1016\/j.pan.2026.04.005"},{"key":"1523_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/bs.apha.2018.04.005","volume":"83","author":"S Srinivasan","year":"2018","unstructured":"Srinivasan S, Yee SW, Giacomini KM. Pharmacogenetics of Antidiabetic Drugs. Adv Pharmacol. 2018;83:361\u201389. https:\/\/doi.org\/10.1016\/bs.apha.2018.04.005.","journal-title":"Adv Pharmacol"},{"key":"1523_CR15","unstructured":"TriNetX. Real-world data for the life sciences and healthcare. Available from: https:\/\/trinetx.com\/"},{"issue":"1","key":"1523_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MPA.0b013e3182571ba9","volume":"42","author":"CH Tseng","year":"2013","unstructured":"Tseng CH. New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas. 2013;42(1):42\u20138. https:\/\/doi.org\/10.1097\/MPA.0b013e3182571ba9.","journal-title":"Pancreas"},{"issue":"4","key":"1523_CR17","first-page":"394","volume":"31","author":"R Sendor","year":"2022","unstructured":"Sendor R, St\u00fcrmer T. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31(4):394\u2013403.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1523_CR18","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","volume":"92","author":"R Huxley","year":"2005","unstructured":"Huxley R, Ansary-Moghaddam A, Berrington de Gonz\u00e1lez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076\u201383.","journal-title":"Br J Cancer"},{"issue":"13","key":"1523_CR19","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ejca.2011.03.003","volume":"47","author":"Q Ben","year":"2011","unstructured":"Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928\u201337.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1523_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3275\/8367","volume":"36","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA. Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest. 2013;36(3):168\u201373. https:\/\/doi.org\/10.3275\/8367.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"1523_CR21","doi-asserted-by":"publisher","first-page":"e92175","DOI":"10.7759\/cureus.92175","volume":"17","author":"A Ahmed","year":"2025","unstructured":"Ahmed A, Tan Z, Abd El-Radi W, Rajamani K. Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2025;17(9):e92175. https:\/\/doi.org\/10.7759\/cureus.92175.","journal-title":"Cureus"},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"413782","DOI":"10.1155\/2012\/413782","volume":"2012","author":"MC Hsieh","year":"2012","unstructured":"Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782. https:\/\/doi.org\/10.1155\/2012\/413782.","journal-title":"Exp Diabetes Res"},{"issue":"6","key":"1523_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00592-013-0471-0","volume":"50","author":"CH Tseng","year":"2013","unstructured":"Tseng CH. Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan. Acta Diabetol. 2013;50(6):879\u201386. https:\/\/doi.org\/10.1007\/s00592-013-0471-0.","journal-title":"Acta Diabetol"},{"issue":"2","key":"1523_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","volume":"66","author":"C Cao","year":"2019","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66(2):157\u201365. https:\/\/doi.org\/10.1007\/s12020-019-02055-z.","journal-title":"Endocrine"},{"issue":"5","key":"1523_CR25","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/edm2.70113","volume":"8","author":"J Wen","year":"2025","unstructured":"Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8(5):e70113. https:\/\/doi.org\/10.1002\/edm2.70113.","journal-title":"Endocrinol Diabetes Metab"},{"key":"1523_CR26","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, Li R. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front Pharmacol. 2022;13:925377. https:\/\/doi.org\/10.3389\/fphar.2022.925377.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1523_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2011-2407","volume":"97","author":"B Gier","year":"2012","unstructured":"Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121\u201331. https:\/\/doi.org\/10.1210\/jc.2011-2407.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1523_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","volume":"53","author":"JS Nachnani","year":"2010","unstructured":"Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53(1):153\u20139. https:\/\/doi.org\/10.1007\/s00125-009-1515-4.","journal-title":"Diabetologia"},{"issue":"1","key":"1523_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150\u20136. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018.","journal-title":"Gastroenterology"},{"issue":"2","key":"1523_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers18020179","volume":"18","author":"S Ailawadi","year":"2026","unstructured":"Ailawadi S, Murphy JE, Storandt MH, Mahipal A. Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. Cancers (Basel). 2026;18(2):179. https:\/\/doi.org\/10.3390\/cancers18020179.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1523_CR31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer\u2014viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"1523_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4093\/dmj.2020.0250","volume":"45","author":"AMY Zhang","year":"2021","unstructured":"Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(3):285\u2013311.","journal-title":"Diabetes Metab J"},{"issue":"20","key":"1523_CR33","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.3390\/cancers13205067","volume":"13","author":"G Eibl","year":"2021","unstructured":"Eibl G, Rozengurt E. Obesity and pancreatic cancer: insight into mechanisms. Cancers (Basel). 2021;13(20):5067.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1523_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","volume":"98","author":"RJ Glynn","year":"2006","unstructured":"Glynn RJ, Schneeweiss S, St\u00fcrmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"1523_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"1523_CR36","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305.","journal-title":"JAMA Netw Open"},{"key":"1523_CR37","doi-asserted-by":"publisher","first-page":"107401","DOI":"10.1016\/j.phrs.2024.107401","volume":"208","author":"G Figlioli","year":"2024","unstructured":"Figlioli G, Boggi U, Gentiluomo M, et al. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2024;208:107401.","journal-title":"Pharmacol Res"},{"issue":"7","key":"1523_CR38","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2337\/db09-0058","volume":"58","author":"AV Matveyenko","year":"2009","unstructured":"Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58(7):1604\u201315. https:\/\/doi.org\/10.2337\/db09-0058.","journal-title":"Diabetes"},{"issue":"12","key":"1523_CR39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/dom.12379","volume":"16","author":"M Gokhale","year":"2014","unstructured":"Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, St\u00fcrmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab. 2014;16(12):1247\u201356. https:\/\/doi.org\/10.1111\/dom.12379.","journal-title":"Diabetes Obes Metab"},{"issue":"57","key":"1523_CR40","doi-asserted-by":"publisher","first-page":"96753","DOI":"10.18632\/oncotarget.18239","volume":"8","author":"CH Tseng","year":"2017","unstructured":"Tseng CH. Sitagliptin and oral cancer risk in type 2 diabetes patients. Oncotarget. 2017;8(57):96753\u201360. https:\/\/doi.org\/10.18632\/oncotarget.18239.","journal-title":"Oncotarget"},{"issue":"11","key":"1523_CR41","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1902\/jop.2009.090233","volume":"80","author":"P Aemaimanan","year":"2009","unstructured":"Aemaimanan P, Sattayasai N, Wara-aswapati N, Pitiphat W, Suwannarong W, Prajaneh S, Taweechaisupapong S. Alanine aminopeptidase and dipeptidyl peptidase IV in saliva of chronic periodontitis patients. J Periodontol. 2009;80(11):1809\u201314. https:\/\/doi.org\/10.1902\/jop.2009.090233.","journal-title":"J Periodontol"},{"issue":"9","key":"1523_CR42","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1097\/MPA.0000000000001130","volume":"47","author":"CH Tseng","year":"2018","unstructured":"Tseng CH. Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. Pancreas. 2018;47(9):e57\u20139. https:\/\/doi.org\/10.1097\/MPA.0000000000001130.","journal-title":"Pancreas"},{"issue":"3","key":"1523_CR43","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1159\/000493214","volume":"49","author":"G Wan","year":"2018","unstructured":"Wan G, Sun X, Li F, Wang X, Li C, Li H, Yu X, Cao F. Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis. Cell Physiol Biochem. 2018;49(3):837\u201347. https:\/\/doi.org\/10.1159\/000493214.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"1523_CR44","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/ijc.32254","volume":"145","author":"M Wei","year":"2019","unstructured":"Wei M, Liu Y, Bi Y, Zhang ZJ. Metformin and pancreatic cancer survival: Real effect or immortal time bias? Int J Cancer. 2019;145(7):1822\u20138. https:\/\/doi.org\/10.1002\/ijc.32254.","journal-title":"Int J Cancer"},{"issue":"5","key":"1523_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4082\/kjfm.22.0005","volume":"43","author":"J Kim","year":"2022","unstructured":"Kim J, Bae YJ, Kang HT. Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort Database. Korean J Fam Med. 2022;43(5):327\u201333. https:\/\/doi.org\/10.4082\/kjfm.22.0005.","journal-title":"Korean J Fam Med"},{"issue":"3","key":"1523_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Li L, Kaelber DC, Xu R. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J Natl Cancer Inst. 2025;117(3):476\u201385. https:\/\/doi.org\/10.1093\/jnci\/djae260.","journal-title":"J Natl Cancer Inst"},{"key":"1523_CR47","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","volume":"164","author":"MK Parr","year":"2019","unstructured":"Parr MK, Joseph JF. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. J Pharm Biomed Anal. 2019;164:536\u201349. https:\/\/doi.org\/10.1016\/j.jpba.2018.11.010.","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"1523_CR48","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.7326\/M24-0019","volume":"177","author":"YH Yeo","year":"2024","unstructured":"Yeo YH, Rezaie A, Hsieh TY, Hu X, Gaddam S, Ma KS, Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed G, Lee GY, Huang PC, Watson R. Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis. Ann Intern Med. 2024;177(9):1289\u201391. https:\/\/doi.org\/10.7326\/M24-0019","journal-title":"Ann Intern Med"},{"issue":"4","key":"1523_CR49","first-page":"178","volume":"10","author":"KL Tran","year":"2017","unstructured":"Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, Nguyen QT. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2017;10(4):178\u201388.","journal-title":"Am Health Drug Benefits"},{"key":"1523_CR50","doi-asserted-by":"crossref","unstructured":"Vahratian A, Warren A. NCHS Data Brief. 2025;53710.15620\/cdc\/174616. GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024.","DOI":"10.15620\/cdc\/174616"},{"issue":"1","key":"1523_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-020-01211-4","volume":"20","author":"CY Yang","year":"2021","unstructured":"Yang CY, Chen YR, Ou HT, Kuo S. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol. 2021;20(1):21. https:\/\/doi.org\/10.1186\/s12933-020-01211-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"1523_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","volume":"11","author":"Y Xie","year":"2023","unstructured":"Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023;11(9):644\u201356. https:\/\/doi.org\/10.1016\/S2213-8587(23)00171-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1523_CR53","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","volume":"164","author":"NM Maruthur","year":"2016","unstructured":"Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740\u201351. https:\/\/doi.org\/10.7326\/M15-2650.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01523-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:06:05Z","timestamp":1789524365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01523-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"221"}}